NPS Hopes For A Happy New Year With Catalysts And Growth Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
The new year is set to be a pivotal one for the rare disease specialist, which expects to launch its short bowel disease drug teduglutide in Europe and have a second product, Natpara, approved in the U.S.
You may also be interested in...
NPS Executes On Ultra-Orphan Gattex Launch With FDA Approval In Hand
NPS Pharmaceuticals will price the short bowel syndrome treatment at $295,000 per year – in line with the cost of other drugs in the ultra-orphan spectrum and higher than some industry observers expected – but said the addressable patient population is lower than it previously estimated.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.